US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
1. FDA approves monthly maintenance dosing for Biogen's Leqembi drug. 2. This expands market access for Alzheimer's treatment.
FAQ
Why Bullish?
FDA approvals typically boost biotech stock prices, especially for drugs in demand. Similar approvals in the past have led to significant price increases for Biogen's products.
How important is it?
The FDA approval speaks directly to Leqembi's market potential, impacting BIIB's valuation considerably.
Why Short Term?
Increased access may lead to short-term sales boosts, impacting near-term revenue. However, long-term effects will depend on market competition and overall drug efficacy.